Copyright Notice
This is a work of the US government and distributed under the terms of the Public Domain
Bookshelf ID: NBK576067
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Chhabra RS, Mahler J, Bristol DW, et al. NTP Genetically Modified Model Report on the Toxicology Studies of Pentaerythritol Triacrylate (Technical Grade) (CASRN 3524-68-3) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice (Dermal Studies): NTP GMM 04 [Internet]. Research Triangle Park (NC): National Toxicology Program; 2005 Oct.
Table D1Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 3-Month Dermal Study of Pentaerythritol Triacrylatea
| Vehicle Control | 0.75 mg/kg | 1.5 mg/kg | 3 mg/kg | 6 mg/kg | 12 mg/kg | |
|---|---|---|---|---|---|---|
| Disposition Summary | ||||||
| Animals initially in study | 10 | 10 | 10 | 10 | 10 | 10 |
| Survivors | ||||||
| Terminal sacrifice | 10 | 10 | 10 | 10 | 10 | 10 |
| Animals examined microscopically | 10 | 10 | 10 | 10 | 10 | 10 |
| Alimentary System | ||||||
| Liver | (10) | (4) | (2) | (2) | (2) | (10) |
| Hepatodiaphragmatic nodule | 3 (30%) | 4 (100%) | 1 (50%) | 2 (100%) | 1 (50%) | 3 (30%) |
| Tongue | (1) | |||||
| Cyst | 1 (100%) | |||||
| Cardiovascular System | ||||||
| Heart | (10) | (10) | ||||
| Cardiomyopathy | 2 (20%) | 2 (20%) | ||||
| Endocrine System | ||||||
| None | ||||||
| General Body System | ||||||
| None | ||||||
| Genital System | ||||||
| Preputial gland | (10) | (10) | ||||
| Inflammation, chronic active | 1 (10%) | 1 (10%) | ||||
| Prostate | (10) | (10) | ||||
| Inflammation, chronic active | 1 (10%) | |||||
| Hematopoietic System | ||||||
| Lymph node, mesenteric | (10) | (10) | ||||
| Hyperplasia | 1 (10%) | |||||
| Integumentary System | ||||||
| Skin | (10) | (10) | (10) | (10) | (10) | (10) |
| Dermis, skin, site of application, inflammation, chronic active | 1 (10%) | 3 (30%) | 10 (100%) | 10 (100%) | 9 (90%) | |
| Epidermis, skin, site of application, degeneration | 1 (10%) | 6 (60%) | 7 (70%) | 7 (70%) | 5 (50%) | |
| Epidermis, skin, site of application, hyperplasia | 1 (10%) | 2 (20%) | 7 (70%) | 9 (90%) | 10 (100%) | 7 (70%) |
| Epidermis, skin, site of application, inflammation, suppurative | 6 (60%) | 3 (30%) | ||||
| Epidermis, skin, site of application, necrosis | 1 (10%) | 1 (10%) | 5 (50%) | 2 (20%) | ||
| Sebaceous gland, skin, site of application, hyperplasia | 2 (20%) | 9 (90%) | 9 (90%) | 10 (100%) | 9 (90%) | |
| Skin, site of application, degeneration | 1 (10%) | |||||
| Skin, site of application, hyperkeratosis | 2 (20%) | 8 (80%) | 10 (100%) | 10 (100%) | 10 (100%) | 9 (90%) |
| Musculoskeletal System | ||||||
| None | ||||||
| Nervous System | ||||||
| None | ||||||
| Respiratory System | ||||||
| Lung | (10) | (10) | ||||
| Inflammation, chronic active | 7 (70%) | 8 (80%) | ||||
| Nose | (10) | (10) | ||||
| Inflammation, acute | 1 (10%) | |||||
| Special Senses System | ||||||
| None | ||||||
| Urinary System | ||||||
| Kidney | (10) | (10) | ||||
| Nephropathy | 4 (40%) | 6 (60%) | ||||
- a
Number of animals examined microscopically at the site and the number of animals with lesion
Table D2Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 3-Month Dermal Study of Pentaerythritol Triacrylatea
| Vehicle Control | 0.75 mg/kg | 1.5 mg/kg | 3 mg/kg | 6 mg/kg | 12 mg/kg | |
|---|---|---|---|---|---|---|
| Disposition Summary | ||||||
| Animals initially in study | 10 | 10 | 10 | 10 | 10 | 10 |
| Survivors | ||||||
| Terminal sacrifice | 10 | 10 | 10 | 10 | 10 | 10 |
| Animals examined microscopically | 10 | 10 | 10 | 10 | 10 | 10 |
| Alimentary System | ||||||
| Liver | (10) | (1) | (4) | (1) | (1) | (10) |
| Hepatodiaphragmatic nodule | 1 (100%) | 3 (75%) | 1 (100%) | 1 (100%) | 2 (20%) | |
| Inflammation, chronic active | 9 (90%) | 4 (40%) | ||||
| Cardiovascular System | ||||||
| Heart | (10) | (10) | ||||
| Cardiomyopathy | 2 (20%) | 1 (10%) | ||||
| Endocrine System | ||||||
| Thyroid gland | (10) | (10) | ||||
| Ultimobranchial cyst | 1 (10%) | 2 (20%) | ||||
| General Body System | ||||||
| None | ||||||
| Genital System | ||||||
| Clitoral gland | (10) | (1) | (10) | |||
| Atrophy | 1 (10%) | |||||
| Cyst | 1 (10%) | 1 (100%) | 1 (10%) | |||
| Ovary | (10) | (1) | (1) | (10) | ||
| Cyst | 1 (100%) | 1 (100%) | ||||
| Uterus | (10) | (10) | ||||
| Hydrometra | 1 (10%) | 5 (50%) | ||||
| Hematopoietic System | ||||||
| Lymph node, mesenteric | (10) | (10) | ||||
| Hyperplasia | 1 (10%) | |||||
| Integumentary System | ||||||
| Skin | (10) | (10) | (10) | (10) | (10) | (10) |
| Dermis, skin, site of application, fibrosis | 1 (10%) | |||||
| Dermis, skin, site of application, inflammation, chronic active | 3 (30%) | 4 (40%) | 9 (90%) | 10 (100%) | ||
| Epidermis, skin, site of application, degeneration | 4 (40%) | 5 (50%) | 5 (50%) | 6 (60%) | ||
| Epidermis, skin, site of application, hyperplasia | 3 (30%) | 8 (80%) | 8 (80%) | 9 (90%) | ||
| Epidermis, skin, site of application, inflammation, suppurative | 4 (40%) | |||||
| Epidermis, skin, site of application, necrosis | 3 (30%) | |||||
| Sebaceous gland, skin, site of application, hyperplasia | 8 (80%) | 8 (80%) | 10 (100%) | 9 (90%) | ||
| Skin, site of application, hyperkeratosis | 4 (40%) | 8 (80%) | 9 (90%) | 10 (100%) | 10 (100%) | |
| Musculoskeletal System | ||||||
| None | ||||||
| Nervous System | ||||||
| None | ||||||
| Respiratory System | ||||||
| Lung | (10) | (10) | ||||
| Inflammation, chronic active | 4 (40%) | 7 (70%) | ||||
| Special Senses System | ||||||
| None | ||||||
| Urinary System | ||||||
| None | ||||||
- a
Number of animals examined microscopically at the site and the number of animals with lesion
Table D3Summary of the Incidence of Nonneoplastic Lesions in Male B6C3F1 Mice in the 3-Month Dermal Study of Pentaerythritol Triacrylatea
| Vehicle Control | 0.75 mg/kg | 1.5 mg/kg | 3 mg/kg | 6 mg/kg | 12 mg/kg | |
|---|---|---|---|---|---|---|
| Disposition Summary | ||||||
| Animals initially in study | 10 | 10 | 10 | 10 | 10 | 10 |
| Survivors | ||||||
| Terminal sacrifice | 10 | 10 | 10 | 10 | 10 | 10 |
| Animals examined microscopically | 10 | 10 | 10 | 10 | 10 | 10 |
| Alimentary System | ||||||
| Liver | (10) | (10) | ||||
| Inflammation, chronic active | 1 (10%) | |||||
| Cardiovascular System | ||||||
| None | ||||||
| Endocrine System | ||||||
| Adrenal cortex | (10) | (10) | ||||
| Subcapsular, hyperplasia | 1 (10%) | |||||
| General Body System | ||||||
| None | ||||||
| Genital System | ||||||
| None | ||||||
| Hematopoietic System | ||||||
| None | ||||||
| Integumentary System | ||||||
| Skin | (10) | (10) | (10) | (10) | (10) | (10) |
| Hyperkeratosis | 1 (10%) | |||||
| Dermis, skin, site of application, fibrosis | 6 (60%) | 10 (100%) | ||||
| Dermis, skin, site of application, inflammation, chronic active | 8 (80%) | 8 (80%) | 10 (100%) | 10 (100%) | ||
| Epidermis, hyperplasia | 1 (10%) | |||||
| Epidermis, inflammation, suppurative | 1 (10%) | |||||
| Epidermis, skin, site of application, degeneration | 5 (50%) | 5 (50%) | 2 (20%) | 4 (40%) | ||
| Epidermis, skin, site of application, hyperplasia | 3 (30%) | 8 (80%) | 9 (90%) | 10 (100%) | ||
| Epidermis, skin, site of application, inflammation, suppurative | 2 (20%) | |||||
| Epidermis, skin, site of application, necrosis | 2 (20%) | 3 (30%) | 7 (70%) | 7 (70%) | ||
| Sebaceous gland, skin, site of application, hyperplasia | 7 (70%) | 9 (90%) | 10 (100%) | 10 (100%) | ||
| Skin, site of application, hyperkeratosis | 5 (50%) | 7 (70%) | 8 (80%) | 6 (60%) | ||
| Skin, site of application, necrosis | 1 (10%) | |||||
| Musculoskeletal System | ||||||
| None | ||||||
| Nervous System | ||||||
| None | ||||||
| Respiratory System | ||||||
| None | ||||||
| Special Senses System | ||||||
| None | ||||||
| Urinary System | ||||||
| Kidney | (10) | (10) | ||||
| Nephropathy | 1 (10%) | |||||
| Urinary bladder | (10) | (10) | ||||
| Edema | 1 (10%) | |||||
- a
Number of animals examined microscopically at the site and the number of animals with lesion
Table D4Summary of the Incidence of Nonneoplastic Lesions in Female B6C3F1 Mice in the 3-Month Dermal Study of Pentaerythritol Triacrylatea
| Vehicle Control | 0.75 mg/kg | 1.5 mg/kg | 3 mg/kg | 6 mg/kg | 12 mg/kg | |
|---|---|---|---|---|---|---|
| Disposition Summary | ||||||
| Animals initially in study | 10 | 10 | 10 | 10 | 10 | 10 |
| Early deaths | ||||||
| Moribund | 1 | |||||
| Natural death | 1 | |||||
| Survivors | ||||||
| Terminal sacrifice | 9 | 10 | 9 | 10 | 10 | 10 |
| Animals examined microscopically | 10 | 10 | 10 | 10 | 10 | 10 |
| Alimentary System | ||||||
| Liver | (10) | (1) | (10) | |||
| Hepatodiaphragmatic nodule | 1 (100%) | |||||
| Inflammation, chronic active | 1 (10%) | 1 (10%) | ||||
| Cardiovascular System | ||||||
| None | ||||||
| Endocrine System | ||||||
| Adrenal cortex | (10) | (10) | ||||
| Accessory adrenal cortical nodule | 1 (10%) | |||||
| Vacuolization cytoplasmic | 6 (60%) | 7 (70%) | ||||
| Subcapsular, hyperplasia | 8 (80%) | 7 (70%) | ||||
| General Body System | ||||||
| None | ||||||
| Genital System | ||||||
| Ovary | (10) | (1) | (9) | |||
| Inflammation, chronic active | 1 (100%) | 1 (11%) | ||||
| Uterus | (10) | (9) | ||||
| Hydrometra | 1 (11%) | |||||
| Hematopoietic System | ||||||
| None | ||||||
| Integumentary System | ||||||
| Skin | (9) | (10) | (10) | (10) | (10) | (10) |
| Dermis, skin, site of application, fibrosis | 9 (90%) | 10 (100%) | ||||
| Dermis, skin, site of application, inflammation, chronic active | 2 (20%) | 5 (50%) | 9 (90%) | 9 (90%) | 10 (100%) | |
| Epidermis, skin, site of application, hyperplasia | 1 (10%) | 2 (20%) | 6 (60%) | 8 (80%) | 10 (100%) | |
| Epidermis, skin, site of application, necrosis | 2 (20%) | 3 (30%) | ||||
| Sebaceous gland, skin, site of application, hyperplasia | 9 (90%) | 9 (90%) | 8 (80%) | 10 (100%) | ||
| Skin, site of application, hyperkeratosis | 1 (10%) | 2 (20%) | 7 (70%) | 7 (70%) | 7 (70%) | |
| Musculoskeletal System | ||||||
| None | ||||||
| Nervous System | ||||||
| None | ||||||
| Respiratory System | ||||||
| None | ||||||
| Special Senses System | ||||||
| None | ||||||
| Urinary System | ||||||
| Kidney | (10) | (10) | ||||
| Nephropathy | 3 (30%) | |||||
| Urinary bladder | (10) | (10) | ||||
| Edema | 1 (10%) | 2 (20%) | ||||
- a
Number of animals examined microscopically at the site and the number of animals with lesion